Pegloticase, an FDA-approved pegylated, recombinant uricase, helps manage chronic gout refractory to standard therapy among adult patients. Since its approval in 2010, this drug has demonstrated efficacy by catalyzing uric acid into the water-soluble purine metabolite allantoin, facilitating its easy excretion. This activity discusses pegloticase’s indications, mechanisms of action, and contraindications, emphasizing its indispensable role in treating and managing chronic gout that remains unresponsive to conventional therapeutic approaches. Attendees will become more knowledgeable about pegloticase therapy, including its adverse event profile, enabling interprofessional team members involved in caring for patients with chronic gout and related conditions to make informed decisions within a clinical setting.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/135221
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABOS - 1.0 Point; Credit Type(s): Accredited CME (ABOS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), Endocrinology, Diabetes, and Metabolism, Foot and Ankle, General Orthopaedics, General Surgery, Geriatric Medicine, Hospital Medicine, Internal Medicine, Rheumatology, Shoulder and Elbow, Surgery of the Hand